Payment overview · 2025
General Payments
$974.08
43 reported records · 15 companies
Healthcare provider profile · identity verified
Malcolm Bernard Franklin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PLAINFIELD, IL · NPI 1043280589
Verified facts
What the public records show
CMS Open Payments records show Malcolm Bernard Franklin, M.D. received $974.08 in general payments during 2025 across 43 reported records.
Lilly USA, LLC accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $141.89 | 14.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $110.46 | 11.3% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $103.34 | 10.6% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $96.86 | 9.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.63 | 9.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.80 | 9.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.23 | 7.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.49 | 5.5% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $47.75 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.89 | 4.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.73 | 3.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.21 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.54 | 2.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.62 | 2.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.64 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $974.08 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $103.34 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.87 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $96.86 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $94.23 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.63 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.63 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $89.80 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.80 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.23 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.49 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.49 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.02 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 403 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 383 | 108 |
| Metformin Hcl | Metformin Hcl | 336 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 103 |
| Losartan Potassium | Losartan Potassium | 315 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 97 |
| Lisinopril | Lisinopril | 282 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 75 |
| Omeprazole | Omeprazole | 231 | 72 |
| Sertraline Hcl | Sertraline Hcl | 213 | 60 |
| Simvastatin | Simvastatin | 200 | 57 |
| Gabapentin | Gabapentin | 186 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 64 |
| Tramadol Hcl | Tramadol Hcl | 179 | 41 |
| Meloxicam | Meloxicam | 163 | 60 |
| Furosemide | Furosemide | 147 | 43 |
| Alprazolam | Alprazolam | 140 | 38 |
| Trazodone Hcl | Trazodone Hcl | 134 | 46 |
| Montelukast Sodium | Montelukast Sodium | 129 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 38 |
| Carvedilol | Carvedilol | 124 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 112 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 45 |
| Eliquis | Apixaban | 99 | 19 |
| Prednisone | Prednisone | 97 | 43 |
| Metformin Hcl Er | Metformin Hcl | 96 | 30 |
| Glipizide Er | Glipizide | 94 | 36 |
| Allopurinol | Allopurinol | 92 | 24 |
| Ezetimibe | Ezetimibe | 87 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 37 |
| Valsartan | Valsartan | 83 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 81 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 26 |
| Potassium Chloride | Potassium Chloride | 79 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 16 |
| Finasteride | Finasteride | 62 | 18 |
| Januvia | Sitagliptin Phosphate | 62 | 12 |
| Irbesartan | Irbesartan | 61 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 17 |
| Clonazepam | Clonazepam | 59 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 14 |
| Jardiance | Empagliflozin | 49 | 15 |
| Celecoxib | Celecoxib | 48 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 15 |
| Baclofen | Baclofen | 47 | 23 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 44 | 13 |
| Ozempic | Semaglutide | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 12 |
| Glimepiride | Glimepiride | 43 | 14 |
| Alendronate Sodium | Alendronate Sodium | 42 | 14 |
| Lovastatin | Lovastatin | 39 | 11 |
| Ramipril | Ramipril | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 13 |
| Warfarin Sodium | Warfarin Sodium | 38 | 12 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 15 |
| Azelastine Hcl | Azelastine Hcl | 36 | 26 |
| Famotidine | Famotidine | 36 | 15 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 13 |
| Azithromycin | Azithromycin | 34 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Bupropion Xl | Bupropion Hcl | 31 | 12 |
| Temazepam | Temazepam | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 22 |
| Atenolol | Atenolol | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $974.08 · 43 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SPRAVATO, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error